Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (Nasdaq:PPCB) reported Q3 2025/26 results and key corporate milestones. The company is advancing lead asset PRP toward a Phase 1b first-in-human study in advanced solid tumor patients and strengthening its anti-aging and cancer research portfolio via a multi-year Spanish university collaboration.
Propanc entered a private placement for up to $100 million, received $2 million by March 31 plus a subsequent $0.5 million tranche, reduced liabilities by $2.10 million and cut convertible notes to $55,000, ending the quarter with $14.33 million in assets and $443,702 in cash.
Propanc Biopharma (Nasdaq:PPCB) approved a 1-for-25 reverse stock split of its common shares, effective before market open on May 18, 2026. The split will proportionally reduce outstanding shares, with fractional shares rounded up, and will not change the par value.
The stock will continue trading on Nasdaq under the symbol PPCB with a new CUSIP 74346N800. Propanc states the reverse split is intended to help restore compliance with Nasdaq’s $1.00 minimum bid price and support its growth plans.
Propanc Biopharma (Nasdaq: PPCB) executed a multi-year joint research collaboration with the Universities of Jaén and Granada, Spain, marking the fifth agreement over a 17-year relationship. The partnership supports evaluation of a senescence-modulating compound, aims to bolster recently filed fibrosis and cancer patent claims, and will run experiments over the next two years to strengthen intellectual property and mechanistic data while leveraging UJA and UGR in vitro and in vivo facilities.
Propanc Biopharma (Nasdaq: PPCB) announced preclinical results for its lead proenzyme therapy PRP, reporting >85% tumor growth inhibition in pancreatic cancer models and plans for Phase 1b First‑In‑Human trials in 2026. The company cited PRP's chemo‑sensitizing effects, reduced fibrosis, stem‑cell targeting, and a $100M facility to support development.
Propanc positions PRP as a potential therapy for advanced solid tumors with initial focus on pancreatic and ovarian cancers; human efficacy and regulatory outcomes remain pending.
Propanc Biopharma (Nasdaq: PPCB) executed a service agreement with FyoniBio to develop and validate an LC-MS pharmacokinetics (PK) assay for its lead asset PRP (trypsinogen and chymotrypsinogen plus activated enzymes) to support a Phase 1b First‑In‑Human study in advanced solid tumor patients. The assay aims for ≤0.1µg/mL sensitivity to quantify four serum analytes. Propanc cites assay validation, GMP manufacture of PRP, and a clinical trial application as three key preparatory activities, and plans to commence the FIH study in the fourth calendar quarter of 2026.
Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors. Key points: >85% tumor growth inhibition in pancreatic models, FDA Orphan Drug status for pancreatic cancer, a $100M funding facility, new patents, and a planned Phase 1b first‑in‑human trial in 2026 for 30–40 advanced solid tumor patients.
The company positions PRP as a multi‑targeted approach that may sensitize tumors, reduce fibrosis and resistance markers, and potentially lower toxicity versus standard therapies.
Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and half yearly results to Dec 31, 2025. Highlights include four provisional patent filings expected to expand IP from ~90 to >200 patents, a peer‑reviewed publication on PRP in PDAC fibroblasts, and a private placement facility up to $100 million.
Financials: total assets $15.11M, convertible notes reduced to $55,000, quarter‑end cash $561,237, and initial proceeds of $1.5M received under the Series C facility.
Propanc Biopharma (Nasdaq: PPCB) highlighted its lead proenzyme therapy PRP, an IV combination of trypsinogen and chymotrypsinogen targeting cancer stem cells, EMT, angiogenesis and metastasis. Preclinical studies showed >85% tumor growth inhibition. FDA Orphan Drug Designation for pancreatic cancer was granted in 2017. A Phase 1b first-in-human study of ~30–40 patients is planned for 2026, with provisional patents and IP grants supporting formulations and production methods. Market estimates cited a $3.25B pancreatic cancer market in 2025, rising to $3.70B in 2026 and to $10.25B by 2034.
Propanc Biopharma (Nasdaq: PPCB) on Jan 27, 2026 filed a fourth provisional patent application in two months with IP Australia covering improved formulations of pancreatic proenzymes trypsinogen and chymotrypsinogen, the active components of its lead asset PRP. The filing targets stability, storage, freeze/thaw resilience and global transport challenges for proenzyme pharmaceutical compositions used in cancer and chronic diseases.
The company said these provisional filings, as they move to national phase entry, are expected to expand its patent estate from ~90 to >200 patents across compositions, formulations, treatment methods and indications, and support preparations for a Phase 1b first-in-human study in advanced cancer patients.
Propanc Biopharma (NASDAQ:PPCB) filed a new provisional patent application with IP Australia on January 20, 2026 for methods to produce fully synthetic recombinant trypsinogen and chymotrypsinogen (Rec-PRP).
The filing describes an optimized yeast-based expression system to manufacture a world-first fully synthetic version of PRP intended as a long-term therapy to treat and prevent metastatic cancer from solid tumors. Management says Rec-PRP could enable long shelf life without refrigeration, scalable lot-consistent supply without animal sourcing, and improved global distribution. The release cites a projected global metastatic cancer market of $111 billion by 2027 and frames the provisional as the third filing in two months to expand the company IP portfolio ahead of national phase filings worldwide.